{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:10:25Z","timestamp":1761491425686,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T00:00:00Z","timestamp":1655856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Kyungsung University Research Grants","award":["2021011"],"award-info":[{"award-number":["2021011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s00228-022-03347-6","type":"journal-article","created":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T01:02:13Z","timestamp":1655859733000},"page":"1365-1376","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety evaluation of oral calcitonin-gene\u2013related peptide receptor antagonists in patients with acute migraine: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"78","author":[{"given":"Seoyeon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4595-9376","authenticated-orcid":false,"given":"Christine E.","family":"Staatz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4796-8564","authenticated-orcid":false,"given":"Nayoung","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9538-0565","authenticated-orcid":false,"given":"In-hwan","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,22]]},"reference":[{"key":"3347_CR1","doi-asserted-by":"publisher","unstructured":"Kowalska M, Prendecki M, Kozubski W, Lianeri M, Dorszewska J (2016) Molecular factors in migraine. Oncotarget 7(31):50708. https:\/\/doi.org\/10.18632\/oncotarget.9367","DOI":"10.18632\/oncotarget.9367"},{"key":"3347_CR2","doi-asserted-by":"publisher","unstructured":"Burch R, Rizzoli P, Loder E (2018) The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache: J Head Face Pain 58(4):496\u2013505. https:\/\/doi.org\/10.1111\/head.13281","DOI":"10.1111\/head.13281"},{"issue":"10","key":"3347_CR3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0333102416657147","volume":"37","author":"M Viana","year":"2017","unstructured":"Viana M, Sances G, Linde M, Ghiotto N, Guaschino E, Allena M, Terrazzino S, Nappi G, Goadsby PJ, Tassorelli C (2017) Clinical features of migraine aura: results from a prospective diary-aided study. Cephalalgia 37(10):979\u2013989. https:\/\/doi.org\/10.1177\/0333102416657147","journal-title":"Cephalalgia"},{"issue":"2","key":"3347_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S1474-4422(17)30435-0","volume":"17","author":"A Charles","year":"2018","unstructured":"Charles A (2018) The pathophysiology of migraine: implications for clinical management. Lancet Neurol 17(2):174\u2013182. https:\/\/doi.org\/10.1016\/S1474-4422(17)30435-0","journal-title":"Lancet Neurol"},{"issue":"4","key":"3347_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1046\/j.1468-2982.1992.1204221.x","volume":"12","author":"BK Rasmussen","year":"1992","unstructured":"Rasmussen BK, Olesen J (1992) Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 12(4):221\u2013228. https:\/\/doi.org\/10.1046\/j.1468-2982.1992.1204221.x","journal-title":"Cephalalgia"},{"key":"3347_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107528","volume":"211","author":"T de Vries","year":"2020","unstructured":"de Vries T, Villal\u00f3n CM, MaassenVanDenBrink A (2020) Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther 211:107528. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107528","journal-title":"Pharmacol Ther"},{"issue":"Suppl 1","key":"3347_CR7","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1111\/j.1526-4610.2004.04106.x","volume":"44","author":"V Papademetriou","year":"2004","unstructured":"Papademetriou V (2004) Cardiovascular risk assessment and triptans. Headache 44(Suppl 1):S31-39. https:\/\/doi.org\/10.1111\/j.1526-4610.2004.04106.x","journal-title":"Headache"},{"issue":"1","key":"3347_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s10194-019-1038-4","volume":"20","author":"EC Agostoni","year":"2019","unstructured":"Agostoni EC, Barbanti P, Calabresi P, Colombo B, Cortelli P, Frediani F, Geppetti P, Grazzi L, Leone M, Martelletti P, Pini LA, Prudenzano MP, Sarchielli P, Tedeschi G, Russo A (2019) Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain 20(1):92. https:\/\/doi.org\/10.1186\/s10194-019-1038-4","journal-title":"J Headache Pain"},{"key":"3347_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.174902","volume":"22","author":"JBR Dos Santos","year":"2022","unstructured":"Dos Santos JBR, da Silva MRR (2022) Small molecule CGRP receptor antagonists for the preventive treatment of migraine: a review. Eur J Pharmacol 22:174902. https:\/\/doi.org\/10.1016\/j.ejphar.2022.174902","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"3347_CR10","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3969\/j.issn.1673-5374.2013.10.009","volume":"8","author":"G Yao","year":"2013","unstructured":"Yao G, Yu T, Han X, Mao X, Li B (2013) Therapeutic effects and safety of olcegepant and telcagepant for migraine: a meta-analysis. Neural Regen Res 8(10):938\u2013947. https:\/\/doi.org\/10.3969\/j.issn.1673-5374.2013.10.009","journal-title":"Neural Regen Res"},{"issue":"2","key":"3347_CR11","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/papr.12158","volume":"15","author":"XP Cui","year":"2015","unstructured":"Cui XP, Ye JX, Lin H, Mu JS, Lin M (2015) Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis. Pain Pract 15(2):124\u2013131. https:\/\/doi.org\/10.1111\/papr.12158","journal-title":"Pain Pract"},{"issue":"1","key":"3347_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3109\/00207454.2015.1137915","volume":"127","author":"P Hong","year":"2017","unstructured":"Hong P, Liu Y (2017) Calcitonin gene-related peptide antagonism for acute treatment of migraine: a meta-analysis. Int J Neurosci 127(1):20\u201327. https:\/\/doi.org\/10.3109\/00207454.2015.1137915","journal-title":"Int J Neurosci"},{"key":"3347_CR13","doi-asserted-by":"publisher","unstructured":"Canlas KM, Macalintal-Canlas RA, Sakai F (2019) Efficacy of calcitonin gene-related peptide antagonists in the treatment of acute migraine: a systematic review and meta-analysis. Acta Medica Philippina 53(1):44\u201351. https:\/\/doi.org\/10.47895\/amp.v53i1.223","DOI":"10.47895\/amp.v53i1.223"},{"key":"3347_CR14","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3389\/fphar.2019.01577","volume":"10","author":"B Gao","year":"2019","unstructured":"Gao B, Yang Y, Wang Z, Sun Y, Chen Z, Zhu Y, Wang Z (2019) Efficacy and safety of rimegepant for the acute treatment of migraine: evidence from randomized controlled trials. Front Pharmacol 10:1577. https:\/\/doi.org\/10.3389\/fphar.2019.01577","journal-title":"Front Pharmacol"},{"issue":"7","key":"3347_CR15","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1111\/head.13858","volume":"60","author":"TLH Chan","year":"2020","unstructured":"Chan TLH, Cowan RP, Woldeamanuel YW (2020) Calcitonin gene-related peptide receptor antagonists (gepants) for the acute treatment of nausea in episodic migraine: a systematic review and meta-analysis. Headache 60(7):1489\u20131499. https:\/\/doi.org\/10.1111\/head.13858","journal-title":"Headache"},{"key":"3347_CR16","doi-asserted-by":"publisher","unstructured":"Diao Y, Yang H, Zhou YC, Du B (2020) The efficacy and tolerability of ubrogepant for episodic migraine: a systematic review and meta-analysis. Reserch Square, Preprint:version 2. https:\/\/doi.org\/10.21203\/rs.2.20666\/v2","DOI":"10.21203\/rs.2.20666\/v2"},{"issue":"8","key":"3347_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1701","volume":"10","author":"P Hong","year":"2020","unstructured":"Hong P, Tan T, Liu Y, Xiao J (2020) Gepants for abortive treatment of migraine: a network meta-analysis. Brain Behav 10(8):e01701. https:\/\/doi.org\/10.1002\/brb3.1701","journal-title":"Brain Behav"},{"issue":"5","key":"3347_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40263-020-00715-7","volume":"34","author":"Y Yang","year":"2020","unstructured":"Yang Y, Chen M, Sun Y, Gao B, Chen Z, Wang Z (2020) Safety and efficacy of ubrogepant for the acute treatment of episodic migraine: a meta-analysis of randomized clinical trials. CNS Drugs 34(5):463\u2013471. https:\/\/doi.org\/10.1007\/s40263-020-00715-7","journal-title":"CNS Drugs"},{"issue":"2","key":"3347_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40261-020-00997-1","volume":"41","author":"DK Ha","year":"2021","unstructured":"Ha DK, Kim MJ, Han N, Kwak J-H, Baek I-h (2021) Comparative efficacy of oral calcitonin-gene\u2013related peptide antagonists for the treatment of acute migraine: updated meta-analysis. Clin Drug Investigation 41(2):119\u2013132. https:\/\/doi.org\/10.1007\/s40261-020-00997-1","journal-title":"Clin Drug Investigation"},{"issue":"1","key":"3347_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/14737167.2021.1945444","volume":"22","author":"K Johnston","year":"2021","unstructured":"Johnston K, Popoff E, Deighton A, Dabirvaziri P, Harris L, Thiry A, Croop R, Coric V, L\u2019Italien G, Moren J (2021) Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. Expert Rev Pharmacoecon Outcomes Res 22(1):155\u2013166. https:\/\/doi.org\/10.1080\/14737167.2021.1945444","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"3347_CR21","doi-asserted-by":"publisher","unstructured":"Kim J, Pak K, Lee GH, Cho JW (2021) Effect of calcitonin gene-related peptide receptor antagonists on migraine treatment: a meta-analysis Reserch Square, Preprint:version 1. https:\/\/doi.org\/10.1159\/000521697","DOI":"10.1159\/000521697"},{"issue":"8","key":"3347_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024741","volume":"100","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Shu Y, Diao Y, Du Y, Chen L, Liu Y, Du B (2021) Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: a meta-analysis. Medicine (Baltimore) 100(8):e24741. https:\/\/doi.org\/10.1097\/MD.0000000000024741","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"3347_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1526-4610.2011.02052.x","volume":"52","author":"TW Ho","year":"2012","unstructured":"Ho TW, Ho AP, Chaitman BR, Johnson C, Mathew NT, Kost J, Fan X, Aurora SK, Brandes JL, Fei K, Beebe L, Lines C, Krucoff MW (2012) Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. Headache 52(2):224\u2013235. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.02052.x","journal-title":"Headache"},{"issue":"23","key":"3347_CR24","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"381","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A (2019) Ubrogepant for the treatment of migraine. N Engl J Med 381(23):2230\u20132241. https:\/\/doi.org\/10.1056\/NEJMoa1813049","journal-title":"N Engl J Med"},{"issue":"2","key":"3347_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ (2019) Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 381(2):142\u2013149. https:\/\/doi.org\/10.1056\/NEJMoa1811090","journal-title":"N Engl J Med"},{"key":"3347_CR26","unstructured":"A pharmacokinetic study of MK-1602 in the treatment of acute migraine (MK-1602-007). https:\/\/ClinicalTrials.gov\/show\/NCT01657370. Accessed 30 Jul\u00a02021"},{"issue":"5","key":"3347_CR27","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1177\/0333102410388435","volume":"31","author":"HC Diener","year":"2011","unstructured":"Diener HC, Barbanti P, Dahl\u00f6f C, Reuter U, Habeck J, Podhorna J (2011) BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 31(5):573\u2013584. https:\/\/doi.org\/10.1177\/0333102410388435","journal-title":"Cephalalgia"},{"issue":"6","key":"3347_CR28","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1177\/0333102411398399","volume":"31","author":"DJ Hewitt","year":"2011","unstructured":"Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, Bachman R, Taraborelli D, Fan X, Assaid C, Lines C, Ho TW (2011) Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 31(6):712\u2013722. https:\/\/doi.org\/10.1177\/0333102411398399","journal-title":"Cephalalgia"},{"issue":"4","key":"3347_CR29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1526-4610.2011.01860.x","volume":"51","author":"DJ Hewitt","year":"2011","unstructured":"Hewitt DJ, Martin V, Lipton RB, Brandes J, Ceesay P, Gottwald R, Schaefer E, Lines C, Ho TW (2011) Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine. Headache 51(4):533\u2013543. https:\/\/doi.org\/10.1111\/j.1526-4610.2011.01860.x","journal-title":"Headache"},{"issue":"12","key":"3347_CR30","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1212\/WNL.0b013e3181b87942","volume":"73","author":"KM Connor","year":"2009","unstructured":"Connor KM, Shapiro RE, Diener HC, Lucas S, Kost J, Fan X, Fei K, Assaid C, Lines C, Ho TW (2009) Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 73(12):970\u2013977. https:\/\/doi.org\/10.1212\/WNL.0b013e3181b87942","journal-title":"Neurology"},{"issue":"12","key":"3347_CR31","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1177\/0333102410370878","volume":"30","author":"AP Ho","year":"2010","unstructured":"Ho AP, Dahl\u00f6f CG, Silberstein SD, Saper JR, Ashina M, Kost JT, Froman S, Leibensperger H, Lines CR, Ho TW (2010) Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia 30(12):1443\u20131457. https:\/\/doi.org\/10.1177\/0333102410370878","journal-title":"Cephalalgia"},{"issue":"9656","key":"3347_CR32","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1016\/S0140-6736(08)61626-8","volume":"372","author":"TW Ho","year":"2008","unstructured":"Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK (2008) Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 372(9656):2115\u20132123. https:\/\/doi.org\/10.1016\/S0140-6736(08)61626-8","journal-title":"Lancet"},{"issue":"1","key":"3347_CR33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1526-4610.2010.01799.x","volume":"51","author":"KM Connor","year":"2011","unstructured":"Connor KM, Aurora SK, Loeys T, Ashina M, Jones C, Giezek H, Massaad R, Williams-Diaz A, Lines C, Ho TW (2011) Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache 51(1):73\u201384. https:\/\/doi.org\/10.1111\/j.1526-4610.2010.01799.x","journal-title":"Headache"},{"issue":"16","key":"3347_CR34","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1212\/01.WNL.0000286940.29755.61","volume":"70","author":"TW Ho","year":"2008","unstructured":"Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM (2008) Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70(16):1304\u20131312. https:\/\/doi.org\/10.1212\/01.WNL.0000286940.29755.61","journal-title":"Neurology"},{"issue":"10200","key":"3347_CR35","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394(10200):737\u2013745. https:\/\/doi.org\/10.1016\/S0140-6736(19)31606-X","journal-title":"Lancet"},{"issue":"2","key":"3347_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1177\/0333102413500727","volume":"34","author":"R Marcus","year":"2014","unstructured":"Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ (2014) BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34(2):114\u2013125. https:\/\/doi.org\/10.1177\/0333102413500727","journal-title":"Cephalalgia"},{"issue":"9","key":"3347_CR37","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102416653233","volume":"36","author":"T Voss","year":"2016","unstructured":"Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, Assaid C, Aurora SK, Michelson D (2016) A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia 36(9):887\u2013898. https:\/\/doi.org\/10.1177\/0333102416653233","journal-title":"Cephalalgia"},{"issue":"19","key":"3347_CR38","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.2019.16711","volume":"322","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, Trugman JM (2019) Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA 322(19):1887\u20131898. https:\/\/doi.org\/10.1001\/jama.2019.16711","journal-title":"JAMA"},{"key":"3347_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/164_2018_201","volume":"255","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson L (2019) Role of CGRP in migraine. Handb Exp Pharmacol 255:121\u2013130. https:\/\/doi.org\/10.1007\/164_2018_201","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"3347_CR40","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ncl.2019.07.008","volume":"37","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Holland PR (2019) An update: pathophysiology of migraine. Neurol Clin 37(4):651\u2013671. https:\/\/doi.org\/10.1016\/j.ncl.2019.07.008","journal-title":"Neurol Clin"},{"issue":"12","key":"3347_CR41","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/17434440.2019.1695599","volume":"16","author":"AM Rapoport","year":"2019","unstructured":"Rapoport AM, Lin T (2019) Device profile of the Nerivio\u2122 for acute migraine treatment: overview of its efficacy and safety. Expert Rev Med Devices 16(12):1017\u20131023. https:\/\/doi.org\/10.1080\/17434440.2019.1695599","journal-title":"Expert Rev Med Devices"},{"issue":"5","key":"3347_CR42","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2165\/11630590-000000000-00000","volume":"26","author":"P Tfelt-Hansen","year":"2012","unstructured":"Tfelt-Hansen P, Olesen J (2012) Taking the negative view of current migraine treatments: the unmet needs. CNS Drugs 26(5):375\u2013382. https:\/\/doi.org\/10.2165\/11630590-000000000-00000","journal-title":"CNS Drugs"},{"issue":"10","key":"3347_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28544","volume":"4","author":"C-P Yang","year":"2021","unstructured":"Yang C-P, Liang C-S, Chang C-M, Yang C-C, Shih P-H, Yau Y-C, Tang K-T, Wang S-J (2021) Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open 4(10):e2128544. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28544","journal-title":"JAMA Netw Open"},{"key":"3347_CR44","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3102\/1076998609346961","volume":"35","author":"JC Valentine","year":"2010","unstructured":"Valentine JC, Pigott TD, Rothstein HR (2010) How many studies do you need? A primer on statistical power for meta-analysis. J Educ Behav Stat 35:215\u2013247. https:\/\/doi.org\/10.3102\/1076998609346961","journal-title":"J Educ Behav Stat"},{"key":"3347_CR45","doi-asserted-by":"crossref","unstructured":"Jackson D, Turner R (2017) Power analysis for random-effects meta-analysis. Res Synth Methods 8(3):290\u2013302. https:\/\/doi-org.ezproxy.library.uq.edu.au\/","DOI":"10.1002\/jrsm.1240"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03347-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-022-03347-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-022-03347-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T07:05:42Z","timestamp":1660115142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-022-03347-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,22]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["3347"],"URL":"https:\/\/doi.org\/10.1007\/s00228-022-03347-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2022,6,22]]},"assertion":[{"value":"17 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Results of this study have been partially presented at the 21st annual meeting of the Asian Conference on Clinical Pharmacy, Nagoya, Japan, 11\u201313 February, 2022.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of prior presentation"}},{"value":"The authors declare no competing interests.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}